Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUSNASDAQ:ALIMNASDAQ:BYSINASDAQ:KALV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$3.35+3.7%$3.28$2.71▼$4.73$641.46M1.5998,554 shs834,013 shsALIMAlimera Sciences$5.54$5.55$2.61▼$5.65$290.24M1.25376,318 shsN/ABYSIBeyondSpring$1.70+1.3%$1.52$0.98▼$3.63$68.58M0.1329,333 shs13,252 shsKALVKalVista Pharmaceuticals$12.18+2.4%$12.05$7.30▼$15.50$605.54M0.05418,043 shs542,938 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma0.00%-10.03%+2.87%-3.00%+12.15%ALIMAlimera Sciences0.00%0.00%0.00%0.00%+55.84%BYSIBeyondSpring0.00%-1.47%+51.82%-3.47%-32.39%KALVKalVista Pharmaceuticals0.00%-12.18%+3.57%+29.49%-1.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABUSArbutus Biopharma2.1406 of 5 stars3.50.00.00.03.32.50.6ALIMAlimera SciencesN/AN/AN/AN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/AN/AN/AN/AKALVKalVista Pharmaceuticals3.9936 of 5 stars3.60.00.04.43.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 3.00Buy$5.5064.18% UpsideALIMAlimera Sciences 2.00Hold$6.008.30% UpsideBYSIBeyondSpring 0.00N/AN/AN/AKALVKalVista Pharmaceuticals 3.13Buy$24.83103.89% UpsideCurrent Analyst Ratings BreakdownLatest KALV, ABUS, ALIM, and BYSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2025KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/28/2025ABUSArbutus BiopharmaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/26/2025KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/26/2025KALVKalVista PharmaceuticalsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/14/2025KALVKalVista PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/13/2025KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$6.17M103.95N/AN/A$0.63 per share5.32ALIMAlimera Sciences$99.68M2.91N/AN/A$0.88 per share6.30BYSIBeyondSpring$1.88M36.56N/AN/A($0.91) per share-1.87KALVKalVista PharmaceuticalsN/AN/AN/AN/A$4.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$72.85M-$0.38N/AN/AN/A-1,137.65%-68.18%-51.55%5/15/2025 (Estimated)ALIMAlimera Sciences-$20.13M-$1.57N/A26.38N/A-14.74%-33.70%-9.63%N/ABYSIBeyondSpring-$21.03MN/A0.00∞N/AN/AN/AN/AN/AKALVKalVista Pharmaceuticals-$126.64M-$3.72N/AN/AN/AN/A-103.92%-88.06%7/10/2025 (Estimated)Latest KALV, ABUS, ALIM, and BYSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ABUSArbutus Biopharma-$0.09N/AN/AN/A$2.54 millionN/A5/12/2025N/ABYSIBeyondSpringN/A-$0.06N/A$0.11N/AN/A3/27/2025Q4 2024ABUSArbutus Biopharma-$0.08-$0.07+$0.01-$0.07$2.20 million$1.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AALIMAlimera SciencesN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus BiopharmaN/A7.027.02ALIMAlimera Sciences1.802.792.62BYSIBeyondSpringN/A1.82N/AKALVKalVista PharmaceuticalsN/A6.876.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%ALIMAlimera Sciences99.83%BYSIBeyondSpring40.29%KALVKalVista PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma20.30%ALIMAlimera Sciences31.40%BYSIBeyondSpring29.31%KALVKalVista Pharmaceuticals10.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90191.48 million181.91 millionOptionableALIMAlimera Sciences15052.39 million35.94 millionOptionableBYSIBeyondSpring8040.32 million27.59 millionOptionableKALVKalVista Pharmaceuticals10049.72 million44.23 millionOptionableKALV, ABUS, ALIM, and BYSI HeadlinesRecent News About These CompaniesKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Rating of "Buy" by AnalystsMay 12 at 2:20 AM | marketbeat.comReviewing Verrica Pharmaceuticals (NASDAQ:VRCA) and KalVista Pharmaceuticals (NASDAQ:KALV)May 11 at 1:13 AM | americanbankingnews.comDAFNA Capital Management LLC Has $6.88 Million Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)May 10 at 7:30 AM | marketbeat.comSusquehanna Fundamental Investments LLC Takes $680,000 Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)May 5, 2025 | marketbeat.comAllostery Investments LP Purchases Shares of 479,100 KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)May 4, 2025 | marketbeat.comBoxer Capital Management LLC Purchases New Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)May 4, 2025 | marketbeat.comMarshall Wace LLP Purchases 103,072 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)May 3, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Lowers Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)May 2, 2025 | marketbeat.comEmerald Mutual Fund Advisers Trust Has $4.66 Million Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)May 1, 2025 | marketbeat.comXTX Topco Ltd Makes New $267,000 Investment in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)April 28, 2025 | marketbeat.comSilverarc Capital Management LLC Has $5.19 Million Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)April 24, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Trading Up 5.9% - Still a Buy?April 23, 2025 | marketbeat.comWalleye Capital LLC Invests $2.27 Million in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)April 21, 2025 | marketbeat.comVanguard Group Inc. Acquires 104,716 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)April 19, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Rating of "Buy" by BrokeragesApril 18, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by American Century Companies Inc.April 16, 2025 | marketbeat.comThe week in pharma: action, reaction and insight – week to April 11April 13, 2025 | thepharmaletter.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Buys $235,500.00 in StockApril 12, 2025 | insidertrades.comKalVista: Poised For Rare Disease TransformationApril 12, 2025 | seekingalpha.comKalVista subsidiary licenses commercialization rights for sebetralstat in JapanApril 9, 2025 | markets.businessinsider.comKalVista licensing deal with KakenApril 9, 2025 | thepharmaletter.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKALV, ABUS, ALIM, and BYSI Company DescriptionsArbutus Biopharma NASDAQ:ABUS$3.35 +0.12 (+3.72%) Closing price 04:00 PM EasternExtended Trading$3.34 -0.02 (-0.45%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Alimera Sciences NASDAQ:ALIMAlimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.BeyondSpring NASDAQ:BYSI$1.63 -0.05 (-2.92%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.KalVista Pharmaceuticals NASDAQ:KALV$12.18 +0.28 (+2.35%) Closing price 04:00 PM EasternExtended Trading$12.12 -0.05 (-0.45%) As of 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
